Current and Emerging Treatments in Follicular Lymphoma

Experts provide their perspectives on the evolving treatment landscape for patients with follicular lymphoma.

Although the majority of patients with follicular lymphoma have a life expectancy similar to that of the general population, predicting which patients will relapse and finding therapies that provide durable responses in the relapsed or refractory setting remains an ongoing challenge.

Kami J. Maddocks, MD, discusses the role of tazemetostat in patients with EZH2-mutant follicular lymphoma.

Lori A. Leslie, MD, discusses a phase 1b study with tazemetostat plus lenalidomide and rituximab in patients with follicular lymphoma.

Alan P. Z. Skarbnik, MD, discusses the watch-and-wait approach in patients with follicular lymphoma.

John M. Burke, MD, discusses the role of tazemetostat in EZH2-mutated follicular lymphoma.

Kami J. Maddocks, MD, discusses treatment considerations for treatment selection in follicular lymphoma.